Maj-Britt Kaltoft
Corporate Officer/Principal bei Statens Serum Institute
Aktive Positionen von Maj-Britt Kaltoft
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Statens Serum Institute | Corporate Officer/Principal | 01.01.2017 | - |
Karriereverlauf von Maj-Britt Kaltoft
Ehemalige bekannte Positionen von Maj-Britt Kaltoft
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SANUWAVE HEALTH, INC. | Direktor/Vorstandsmitglied | 16.06.2017 | 28.06.2021 |
Independent Dir/Board Member | 16.06.2017 | 28.06.2021 | |
NOVO NORDISK A/S | Corporate Officer/Principal | 01.01.2011 | 01.01.2016 |
EffRx, Inc.
EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co. | Geschäftsführer | 01.11.2010 | 10.06.2011 |
Nycomed Hellas SA | Direktor/Vorstandsmitglied | 01.01.2007 | 01.01.2007 |
H. LUNDBECK A/S | Corporate Officer/Principal | 01.01.2003 | 01.01.2003 |
Takeda A/S
Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Corporate Officer/Principal | - | - |
EffRx Pharmaceuticals SA
EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland. | Geschäftsführer | 13.06.2011 | - |
Ausbildung von Maj-Britt Kaltoft
Seattle University | Graduate Degree |
University of Copenhagen | Doctorate Degree |
Statistik
International
Dänemark | 6 |
Vereinigte Staaten | 4 |
Schweiz | 2 |
Operativ
Corporate Officer/Principal | 4 |
Chief Operating Officer | 2 |
Graduate Degree | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 4 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
NOVO NORDISK A/S | Health Technology |
H. LUNDBECK A/S | Health Technology |
SANUWAVE HEALTH, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
EffRx, Inc.
EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co. | Health Technology |
EffRx Pharmaceuticals SA
EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland. | Health Technology |
Takeda A/S
Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Finance |
Nycomed Hellas SA |
- Börse
- Insiders
- Maj-Britt Kaltoft
- Erfahrung